NEW YORK – India's Trivitron Healthcare said on Monday that it has entered into a strategic partnership with Illumina Singapore to expand the use of next-generation sequencing-based in vitro diagnostics.
Under the terms of the four-year deal, Illumina and Trivitron will develop and distribute a suite of IVD assays for oncology, infectious diseases, and prenatal health. Trivitron will manufacture and market the diagnostic tests following regulatory approvals.
Financial and other terms of the deal were not disclosed.
"Our collaboration with Trivitron will increase access for patients in India to genomics and expand on Illumina's solid history and broad portfolio of partnerships with industry leaders, with the united goal of advancing diagnostics and precision medicine," Gretchen Weightman, Illumina VP and general manager for Asia Pacific and Japan, said in a statement.
Trivitron is a medical technology and manufacturing company based in New Delhi, offering IVDs as well as durable medical products.